Currently, there is a lack of Phase III study data comparing the triple regimen directly with alternative first-line treatment strategies for HR+/HER2- advanced breast cancer patients with PIK3CA mutations and endocrine resistance, precluding direct head-to-head cost-effectiveness comparisons. This evidence concerns the gene ERBB2 and breast carcinoma.